Top Markets
Coin of the day
Petros Pharmaceuticals, Inc. Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc.

PTPI
Rank in Stocks #40525
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male... Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Share Price
$0.0034
Market Cap
$144.07K
Change (1 day)
13.33%
Change (1 year)
-88.67%
Country
US
Trade Petros Pharmaceuticals, Inc. (PTPI)

Category

Operating Margin for Petros Pharmaceuticals, Inc. (PTPI)
Operating Margin as of 2026 TTM: 0.00%
According to Petros Pharmaceuticals, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Petros Pharmaceuticals, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
0.00% -
DE
0.00% -
DE
0.00% -
JP
0.00% -
CH
23.18% -
IN
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.